ERBA Diagnostics, Inc. Announces Notice of Noncompliance

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT Continued Listing Standards and Extension of Compliance Plan

MIAMI, May 20, 2016 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc. (NYSE MKT:ERB) (the “ Company ”), a fully integrated in vitro diagnostics company, announced today that, on May 19, 2016, the Company received a letter from NYSE MKT LLC (the “ Exchange ”) stating that the Exchange has determined that the Company is not in compliance with Sections 134 and 1101 of the Exchange’s Company Guide (the “ Company Guide ”) due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 with the Securities and Exchange Commission.  The letter also states that the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 is a material violation of its listing agreement with the Exchange and, therefore, pursuant to Section 1003(d) of the Company Guide, the Exchange is authorized to suspend and, unless prompt corrective action is taken, remove the Company’s securities from the Exchange. 

In the letter, the Exchange has acknowledged that the Company is already delinquent on its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and its Annual Report on Form 10-K for the year ended December 31, 2015 and has previously submitted a plan of remediation and compliance (the “ Plan ”).  The Company submitted the Plan to the Exchange on December 10, 2015, and the Exchange approved the Plan on January 22, 2016 and granted the Company an extension until May 25, 2016 to regain compliance with the continued listing standards of the Company Guide.

The Company has been in communication with the Exchange and, on May 13, 2016, submitted a supplement to the Plan (the “ Supplement to Plan ”) addressing the Company’s progress with the Plan and how the Company intends to regain compliance with the Company Guide.  In the letter, the Exchange informed the Company that it has accepted the Company’s Supplement to Plan and granted the Company an extension until November 25, 2016 (the “ Plan Period ”) to regain compliance with the continued listing standards of the Company Guide. The Company will be subject to periodic review by the Exchange during the Plan Period.  Failure to make progress consistent with the Plan or to regain compliance with the continued listing standards of the Company Guide by the end of the Plan Period could result in the Company being delisted from the Exchange.  The Company is working diligently to regain compliance with the Company Guide by November 25, 2016.

About ERBA Diagnostics, Inc. ERBA Diagnostics, Inc. (NYSE MKT:ERB), is a fully integrated in vitro diagnostics company, offering a comprehensive suite of clinical testing products throughout the U.S. and emerging markets.  The Company serves as a one-stop shop for the testing needs of the growing number of smaller hospitals, reference labs, and physician clinics.  ERBA Diagnostics’ line of proprietary and automated instruments, test kits, and reagents provide customers with autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing.  www.erbadiagnostics.com

Safe Harbor Statement Except for the historical matters contained herein, statements in this Current Report on Form 8-K are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be preceded by, followed by or otherwise include the words “may,” “will,” “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “could,” “would,” “should,” or similar expressions or statements that certain events or conditions may occur. These forward-looking statements are based largely on the Company’s expectations and the beliefs and assumptions of the Company’s management and on the information currently available to it and are subject to a number of risks and uncertainties, including, but not limited to, the risks and uncertainties that: the Company may not make progress consistent with the Plan or Supplement to Plan during the Plan Period; the Company may not be able to regain compliance with the Company Guide by November 25, 2016, which would result in the Company’s common stock being delisted by the Exchange; the Exchange may initiate delisting proceedings, which would result in the Company’s common stock being delisted by the Exchange; the Company’s financial results may take longer to prepare than anticipated; the Company may not be able to file its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2015 and March 31, 2016 or its Annual Report on Form 10-K for the year ended December 31, 2015 on or prior to the timeframe set forth above; if the Company does not comply with the timeframe set forth above, then the Company’s common stock may be delisted by the Exchange; during the Company’s period of noncompliance with Sections 134 and 1101 of the Company Guide, the Company’s common stock may be delisted by the Exchange; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements.  See also the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC for further discussion of certain risks and uncertainties that could materially and adversely affect the Company’s business, operating results or financial condition.  Many of these factors are beyond the Company’s control. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in the Company’s filings with the SEC, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.

CONTACT: Contact Details: Mohan Gopalkrishnan Tel: 305 418 2320 Email: g_mohan@erbadiagnostics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 0

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Frontline Healthcare Partners Secures Integracare Inc. Deal

Updated Category News Views 161

Frontline Healthcare Partners Expands Through Strategic Acquisition Frontline Healthcare Partners has recently made headlines with its strategic acquisition of Integracare Inc.. This move indicates a significant step forward in enhancing its portfolio within the private home healthcare space. With Integracare’s reputation for quality care in Toronto and Mississauga,...

Continue Reading
WiMi Innovates with Advanced FPGA-Based Quantum Computing Tech

Updated Category News Views 147

WiMi Hologram Cloud Inc. Develops Cutting-Edge Quantum Computing Technology WiMi Hologram Cloud Inc. (NASDAQ: WiMi), a global leader in Hologram Augmented Reality (AR) technology, has achieved a remarkable milestone by developing a digital quantum computer verification technology based on Field-Programmable Gate Array (FPGA). This advancement signifies a transformative...

Continue Reading
KSP Achieves Excellence in Specialty Pharmacy Recognition Again

Updated Category News Views 244

KSP Recognized as a Specialty Pharmacy Leader KSP, part of McLaren's Specialty Pharmacy, has once again been honored for its outstanding achievements in performance measurement. The Utilization Review Accreditation Commission (URAC) has recognized KSP as a 2024 Specialty Pharmacy Pioneer in its Leaders in Performance Measurement (LPM) program. This accolade underlines...

Continue Reading
Why IREN Limited Shares Are Under Pressure Today in Market

Updated Category News Views 237

Understanding the Recent Drop in IREN Limited Stock IREN Limited (NASDAQ: IREN) has experienced a noticeable decline in share price today as investors react to the company's recent announcements. This comes as a surprise to some, as IREN has shown potential for growth in the past year. Recent Announcements from IREN Limited In a recent update, IREN Limited unveiled plans...

Continue Reading
Deutsche Bank Adjusts S&P 500 Forecast to 5,750 Points

Updated Category News Views 57

Deutsche Bank Updates S&P 500 Year-End Forecast Deutsche Bank has adjusted its year-end target for the S&P 500 index, now forecasting it to reach 5,750 points, up from the previous estimate of 5,500. This significant change stems from strong corporate earnings, an increase in stock buybacks, and a solid demand for equities among investors. Positive Earnings Growth Ahead...

Continue Reading